The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Santa Ana Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $168.34MM | Series B-2 | 6/13/2024 | $62.5MM | $264.43MM | $1.50 | Versant Ventures, TPG, GV, Access Biotechnology, Andreessen Horowitz, RTW Investments | |||||
| Diverge Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $52.4MM | Series A-3 | 10/24/2024 | $19.08MM | $264.39MM | $176.74 | GV | |||||
| Cullgen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $116MM | Series C | 5/8/2023 | $35MM | $264.09MM | $2.63 | AstraZeneca-CICCVentureCapitalPartnership, SincereCapital, VoyagersCapital, WuxiCapitalGroup, GHIGroup | |||||
| SPR Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $104.49MM | Series D-1 | 2/1/2024 | $25.64MM | $263.67MM | $27.44 | Revelation Partners, RC Capital, Mutual Capital Partners | |||||
| NOCD | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $85.23MM | Series C-1 | 1/31/2023 | $8.33MM | $263.2MM | $20.22 | Cigna Ventures, 7wireVentures, Longitude Capital, Kaiser Permanente, F-Prime Capital, Eight Roads Capital, Health Enterprise Partners | |||||
| Pager | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $176.59MM | Series D-1 | 6/2/2022 | $3.04MM | $262.42MM | $0.85 | UndisclosedInvestors | |||||
| TRIANA Biomedicines | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $230.06MM | Series B | 12/3/2025 | $120.06MM | $262.22MM | $3.04 | Ascenta Capital, Bessemer Venture Partners, YK Bioventures, Regeneron Ventures, Invus, Finchley Healthcare Ventures, RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital | |||||
| Immune-Onc Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $143.15MM | Series B3 | 1/6/2023 | $30MM | $262.2MM | $2.11 | Triwise Capital, Proxima Ventures | |||||
| Candid | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $144.62MM | Series A-1 | 7/11/2023 | $7.71MM | $261.94MM | $1.23 | Venrock, F-Prime | |||||
| Ansa Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $57.42MM | Series B Plus | 10/1/2025 | $24.28MM | $260.65MM | $0.35 | Cerberus Ventures, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fall Line Capital, AIM13, Black Opal Ventures | |||||
| Virtual Incision | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $131.49MM | Series C | 9/19/2023 | $76.58MM | $260.17MM | $1.66 | Bluestem Capital, Endeavour Vision, Baird Capital, cultivate(MD) Capital Funds, PrairieGold Venture Partners, Arboretum Ventures, InVivium Capital | |||||
| Xalud Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $72.64MM | Series C | 8/24/2021 | $32.75MM | $259.4MM | $2.80 | PBM Capital Group | |||||
| Alleviant Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $182.73MM | Series 2 | 1/14/2025 | $91.4MM | $258.67MM | $1.28 | Gilde Healthcare, Omega Funds, S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Corporation | |||||
| Escient Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $243.51MM | Series C | 11/28/2022 | $120MM | $256.49MM | $0.75 | NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, Altitude Life Science Ventures | |||||
| Syncromune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $126.01MM | Series A-1 | 8/21/2025 | $99.85MM | $254.93MM | $3.43 | Wasatch Equity Partners | |||||
| ION Clean Energy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $74.4MM | Series A | 4/4/2024 | $74.4MM | $254.58MM | $6.97 | Chevron, Carbon Direct Capital, SK Materials | |||||
| Disc Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $145MM | Series B | 9/2/2021 | $90MM | $253.72MM | $2.40 | OrbiMed, Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, Alexandria Venture Investments, Novo Holdings A/S, Access Biotechnology, Atlas Venture | |||||
| Mesh Optical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $50MM | Series A-1 | 2/17/2026 | $37.93MM | $253.44MM | $16.17 | Thrive Capital, Also Capital, Banner Ventures | |||||
| Goldfinch Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $190.22MM | Series B | 6/30/2020 | $105.91MM | $252.06MM | $1.18 | Eventide Asset Management, Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital, Irving Investors, Gilead Sciences, Yonjin Capital, Schroeder Adveq | |||||
| Two Chairs | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $92.39MM | Series C | 4/16/2024 | $40MM | $250.37MM | $8.00 | Amplo, Fifth Down Capital | |||||
| BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $104.3MM | Series B | 7/20/2022 | $80MM | $249.63MM | $9.24 | Section 32, Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, AME Cloud Ventures | |||||
| Third Pole Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $334.43MM | Series B-4 | 2/16/2023 | $14MM | $249.3MM | $36.51 | Starpath Ventures, Acord Campus Taiwan | |||||
| Neurogene | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $183.58MM | Series B | 12/16/2020 | $115MM | $248.92MM | $2.44 | EcoR1 Capital, Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group | |||||
| Qnovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $49.64MM | Series B | 12/10/2024 | $8MM | $246.21MM | $19.32 | Blue Ledge Capital, Evolution VC Partners, Vice Ventures, Gaingels | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.